← All trials
NCT05715736
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 8, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Feb 8, 2023
- Last posted
- Sep 25, 2023
- Enrollment
- 31
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Syneos HealthLead sponsor
- CMAX Clinical ResearchOverall official - principal investigator
- AprilBio Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.